Golexin (Goserelin) 3.6mg

• In the treatment of metastatic prostate cancer where Golexin has demonstrated comparable survival benefits to surgical castrations
• In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Golexin has demonstrated comparable survival benefits to an anti-androgen
• As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Golexin has demonstrated improved disease-free survival and overall survival
• As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Golexin has demonstrated improved disease-free survival
• As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where Golexin has demonstrated improved disease-free survival

(ii) Advanced breast cancer in pre and perimenopausal women suitable for hormonal manipulation.
(iii) Golexin 3.6 mg is indicated as an alternative to chemotherapy in the standard of care for pre/perimenopausal women with oestrogen receptor (ER) positive early breast cancer.
(iv) Endometriosis: In the management of endometriosis, Golexin alleviates symptoms, including pain, and reduces the size and number of endometrial lesions.
(v) Endometrial thinning: Golexin is indicated for the prethinning of the uterine endometrium prior to endometrial ablation or resection.
(vi) Uterine fibroids: In conjunction with iron therapy in the haematological improvement of anaemic patients with fibroids prior to surgery.
(vii) Assisted reproduction: Pituitary downregulation in preparation for superovulation.